Jennifer Petter
Company: Arrakis Therapeutics Inc.
Job title: Founder and Scientific Chief and Officer
Bio:
Jennifer Petter, Ph.D., is a Founder & Chief Scientific Officer of Arrakis Therapeutics. An experienced drug hunter, scientist, and life science executive, Dr. Petter’s research has spanned different fields over the years, with a current focus on RNA at Arrakis. She is the author or co-author on over 50 papers and over 50 patents and/or patent applications. Prior to creating Arrakis, Dr. Petter was Vice President of Chemistry at Celgene. She joined Celgene after the acquisition of Avila Therapeutics, a startup, in 2012. She has also held roles at Mersana Therapeutics, Biogen, and the Sandoz Research Institute (now a part of Novartis). She is a member of the American Association of Cancer Research (AACR), the Society of Neuro-Oncology, and the RNA Society and an associate member of the American Society of Clinical Oncology (ASCO). Dr. Petter serves on the scientific advisory boards for Cygnal Therapeutics and PIC Therapeutics, and on the boards of directors for OUTBio and Theon Therapeutics. Dr. Petter received her bachelor’s degree from Dartmouth College and her Ph.D. from Duke University. She completed her post-doctorate research at Columbia University.
Seminars:
Emerging Modalities Beyond Splice Modulation: Harnessing Covalent Binders, Proximity-Inducing Compounds & lncRNA Targets to Discover Functional RNA Binders 1:00 pm
While splice modulation has paved the way for RNA-targeted therapeutics, the next frontier lies in unlocking the therapeutic potential of directly targeting RNA. This workshop explores innovative strategies exploring covalently binding RNA, bivalent compounds inducing proximity between RNA and effector molecules, and the untapped opportunity of targeting long non-coding RNAs. Attendees will cover: • Exploring…Read more
day: Pre Conference workshop day
Targeting Pathological RNA in Myotonic Dystrophy (DM1): Advancing a Small Molecule with Intrinsic Activity to Treat a Systemic Disease 3:45 pm
• Harnessing structure-based drug design to develop rSMs to normalize RNA splicing and relieve myotonia • Optimizing the pharmacological properties of an rSM with systemic biodistribution and functional activity in disease-relevant models • Demonstrating molecular correction and phenotypic rescue to support the translational potential of a first-in-class small molecule against DM1Read more
day: Conference Day One
Panel Discussion: Building Strategic Collaborations & Investment Pathways to Accelerate RNA-Targeted Drug Discovery Across Biotech & Pharma 8:45 am
• Discussing the importance of pharma-biotech-academic collaborations and what each sector can provide to successfully create RNA-targeted therapeutics • How are large pharma and biotech companies structuring risk-sharing partnerships to access innovation and accelerate RNA-targeted therapeutic pipelines • How can early-stage companies leverage academic collaborations, tool compound sharing and co development deals to validate targets…Read more
day: Conference Day Two